• Q4 FY26 cash receipts of $4.0M with net positive operating cash inflow of $0.7M
• Full-year FY26 cash receipts of $14.3M with net positive operating cash inflow of $2.9M
• Cash at bank of $4.8M at quarter-end, with a strong net cash position of $2.3M

Resonance Health Limited (ASX: RHT) has released its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter and financial year ended 30 June 2026. The company made significant progress in its three focus areas: Clinical Trial Management CRO Services, Software-as-a-Medical-Device Image Analysis Services, and Clinical Trial Site Services. Key highlights include the completion of recruitment for a major $13.8M clinical trial, a strong SaMD services order book and bid pipeline, and a growing and profitable TrialsWest clinic network. Financial highlights include Q4 FY26 cash receipts of $4.0M with net positive operating cash inflow of $0.7M, and full-year FY26 cash receipts of $14.3M with net positive operating cash inflow of $2.9M. The company ended the quarter with $4.8M in cash and a net cash position of $2.3M.